Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system
about
The evolution of poxvirus vaccinesCanarypox and fowlpox viruses as recombinant vaccine vectors: an ultrastructural comparative analysisThe diversity of T-cell co-stimulation in the induction of antitumor immunity.ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiencyPresent and future of veterinary viral vaccinology: a review.Applications of pox virus vectors to vaccination: an update.Development of a cytomegalovirus vaccine: lessons from recent clinical trials.CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individualsRole of cell signaling in poxvirus-mediated foreign gene expression in mammalian cellsPoxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors.Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains.Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion.Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients.Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2).Vaccine developments.
P2860
Q26995905-C41E1E49-13CD-4F14-A51A-7D34EDE36AF3Q28279303-4230DC5E-14B5-47C1-B264-E998E9C2C84DQ33776121-25306C1A-1047-4A62-B387-CC0DE08781BDQ34326613-AF1906CA-B24C-4853-B81F-5A8E48789FB9Q34341579-58270E89-7F2B-40B3-AB89-709C9058C35FQ34403246-1A279626-9151-43B2-AE18-C884A3327E57Q34451960-A6FB4977-65DC-46CB-9226-7CF61E5F9FD1Q34692141-870244DA-DFE5-47BE-A73E-1E2FECA6500AQ35292450-F9A6AC1D-E9D7-4B7B-80C7-B30136ED931CQ35851786-22164B2C-FEC9-4636-8985-72F4A4582364Q38848322-5755F719-3CA0-4A27-8492-83518D464162Q39597953-C2C95B2A-6D85-43E1-B120-CB570067E771Q40555883-757A1FC2-6DDD-4637-B783-60813700ED64Q45870268-98829AAF-ED4E-4D54-B75C-68D7B6A13699Q46448539-A0C5C99E-55C8-4E7F-BC56-81E407D792B5
P2860
Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system
description
1996 nî lūn-bûn
@nan
1996 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Human safety and immunogenicit ...... rnative poxvirus vector system
@ast
Human safety and immunogenicit ...... rnative poxvirus vector system
@en
Human safety and immunogenicit ...... rnative poxvirus vector system
@nl
type
label
Human safety and immunogenicit ...... rnative poxvirus vector system
@ast
Human safety and immunogenicit ...... rnative poxvirus vector system
@en
Human safety and immunogenicit ...... rnative poxvirus vector system
@nl
prefLabel
Human safety and immunogenicit ...... rnative poxvirus vector system
@ast
Human safety and immunogenicit ...... rnative poxvirus vector system
@en
Human safety and immunogenicit ...... rnative poxvirus vector system
@nl
P2093
P1433
P1476
Human safety and immunogenicit ...... rnative poxvirus vector system
@en
P2093
B Meignier
E K Kauffman
E Paoletti
J Tartaglia
P304
P356
10.1016/0264-410X(95)00171-V
P407
P577
1996-04-01T00:00:00Z